iNKT Publications

Cancer Cell Research Article

Cancer Cell

2018 Oct 08; 34(4):596-610

Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting

See Article Commentary at

iNKT Cells Protect Against Graft Versus Host Disease

2017

Front Immunol

2017 July 31;8:900

Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation

2017

Leukemia

2017 Apr;31(4):903-912

Pre-transplant donor CD4− invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease

2016

Blood

2016 Apr 7;127(14):1828-35

Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival

2015

Blood

2015 May 28;125(22):3374-3375

A party of three: iNKT cells in GVHD prevention

2015

Blood

2015 May 28;125(22):3491-3500

Third-party CD4+ invariant natural killer Tcells protect from murine GVHD lethality

2014

Blood

2014 Nov 20;124(22):3320-3328

CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells

2012

Blood

2012 May 24;119(21):5030-6

Graft invariant natural acutekiller T-cell dose predicts risk of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

2011

Blood

2011 Mar 17;117(11):3220-3229

Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4–dependent mechanism

2010

Transfusion

2010 Feb;50(2):407-17

Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft‐versus‐host disease in allogeneic bone marrow transplantation

2008

J Immunol.

2008 Sep 1;181(5):3268-76

Human Invariant NKT Cells Display Alloreactivity Instructed by Invariant TCR-CD1d Interaction and Killer Ig Receptors

Clinical Use of iNKT Cells

2020

Nat Med

2020 Nov;26(11):1686-1690.

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

2017

Clin Cancer Res.

2017 Jul 15;23(14):3510-3519

Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial

2013

Blood

2013 Jan 17;121(3):423-430

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma

2012

J Clin Immunol.

2012 Apr 26;32(5):1071-81

Accumulation of Activated Invariant Natural Killer T Cells in the Tumor Microenvironment after α-Galactosylceramide-Pulsed Antigen Presenting Cells

2011

Clin Cancer Res.

2011 Aug 1; 17(15):5140-51

Comparison of Clinical and Immunological Effects of Intravenous and Intradermal Administration of α-GalactosylCeramide (KRN7000)-Pulsed Dendritic Cells

2011

Clin Immunol.

2011 Mar;138(3):255-65

Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy

2011

Cancer Immunol Immunother.

2011 Feb;60(2):207-15

Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with HNC

2009

J Immunol.

2009 Feb 15;182(4):2492-501

A Phase I-II Study of α-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured PBMCs in Patients with Advanced and Recurrent NSCLC

2008

Cancer Immunol Immunother.

2008 Mar;57(3):337-45

Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent HNC

2006

Clin Cancer Res.

2006 Oct 15;12(20 Pt 1):6079-86

A Phase I Study of In vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer

2005

J Exp Med.

2005 May 2;201(9):1503-17

Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients

2005

Clin Cancer Res.

2005 Mar 1;11(5):1910-17

A Phase I Study of α-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent NSCLC

2004

Blood

2004 Jan 15;103(2):383-389

Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

2002

Clin Cancer Res.

2002 Dec;8(12):3702-9

A Phase I Study of the Natural Killer T-Cell Ligand α-Galactosylceramide (KRN7000) in Patients with Solid Tumors